2016 Q4 Form 10-Q Financial Statement
#000114420416135413 Filed on November 18, 2016
Income Statement
| Concept | 2016 Q4 | 2016 Q3 | 2015 Q3 |
|---|---|---|---|
| Revenue | $75.00K | $36.00K | $160.0K |
| YoY Change | -44.03% | -77.5% | -80.46% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $2.350M | $2.470M | $1.420M |
| YoY Change | 39.88% | 73.94% | 35.24% |
| % of Gross Profit | |||
| Research & Development | $1.049M | $820.0K | $551.0K |
| YoY Change | 49.01% | 48.82% | -53.5% |
| % of Gross Profit | |||
| Depreciation & Amortization | $326.0K | $324.0K | $1.000K |
| YoY Change | 32500.0% | 32300.0% | 0.0% |
| % of Gross Profit | |||
| Operating Expenses | $3.400M | $3.290M | $1.973M |
| YoY Change | 42.38% | 66.75% | -11.72% |
| Operating Profit | -$3.325M | -$1.813M | |
| YoY Change | 47.52% | 28.04% | |
| Interest Expense | $483.0K | -$470.0K | $0.00 |
| YoY Change | |||
| % of Operating Profit | |||
| Other Income/Expense, Net | -$467.0K | $10.00K | $8.000K |
| YoY Change | -5937.5% | 25.0% | 33.33% |
| Pretax Income | -$3.790M | -$3.610M | -$1.810M |
| YoY Change | 68.44% | 99.45% | 28.37% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$3.229M | -$3.060M | -$1.805M |
| YoY Change | 43.77% | 69.53% | 28.01% |
| Net Earnings / Revenue | -4305.33% | -8500.0% | -1128.13% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$362.5K | -$343.4K | -$234.2K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 89.11M shares | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2016 Q4 | 2016 Q3 | 2015 Q3 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $16.33M | $20.10M | $8.380M |
| YoY Change | 142.64% | 139.86% | 140.11% |
| Cash & Equivalents | $16.33M | $20.10M | $8.384M |
| Short-Term Investments | |||
| Other Short-Term Assets | $290.0K | $130.0K | $90.00K |
| YoY Change | 16.0% | 44.44% | 12.5% |
| Inventory | $30.00K | $0.00 | |
| Prepaid Expenses | |||
| Receivables | $25.00K | $230.0K | $610.0K |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $16.75M | $20.46M | $9.080M |
| YoY Change | 132.58% | 125.33% | 120.33% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $25.45M | $25.58M | $10.00K |
| YoY Change | 181707.14% | 255700.0% | -50.0% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | $1.960M | $2.023M | $2.284M |
| YoY Change | -10.95% | -11.43% | -9.22% |
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $30.00K | $30.00K | |
| YoY Change | |||
| Total Long-Term Assets | $27.44M | $27.63M | $2.294M |
| YoY Change | 1138.83% | 1104.49% | -9.65% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $16.75M | $20.46M | $9.080M |
| Total Long-Term Assets | $27.44M | $27.63M | $2.294M |
| Total Assets | $44.19M | $48.09M | $11.37M |
| YoY Change | 369.29% | 322.82% | 70.78% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $731.0K | $980.0K | $1.270M |
| YoY Change | -45.2% | -22.83% | 146.12% |
| Accrued Expenses | $905.0K | $1.020M | $290.0K |
| YoY Change | 381.38% | 251.72% | -58.69% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $180.0K | $170.0K | |
| YoY Change | |||
| Total Short-Term Liabilities | $1.867M | $2.174M | $1.570M |
| YoY Change | 21.23% | 38.47% | 28.9% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $25.18M | $25.22M | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $25.18M | $25.22M | $0.00 |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $1.867M | $2.174M | $1.570M |
| Total Long-Term Liabilities | $25.18M | $25.22M | $0.00 |
| Total Liabilities | $27.04M | $27.39M | $1.565M |
| YoY Change | 1658.26% | 1650.42% | 28.49% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$63.88M | ||
| YoY Change | 23.14% | ||
| Common Stock | $68.06M | $89.00K | |
| YoY Change | 13.84% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $4.153M | $7.140M | $9.810M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $44.19M | $48.09M | $11.37M |
| YoY Change | 369.29% | 322.96% | 70.8% |
Cashflow Statement
| Concept | 2016 Q4 | 2016 Q3 | 2015 Q3 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$3.229M | -$3.060M | -$1.805M |
| YoY Change | 43.77% | 69.53% | 28.01% |
| Depreciation, Depletion And Amortization | $326.0K | $324.0K | $1.000K |
| YoY Change | 32500.0% | 32300.0% | 0.0% |
| Cash From Operating Activities | -$3.570M | -$2.273M | -$1.150M |
| YoY Change | 115.06% | 97.65% | 101.75% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$170.0K | $400.0K | $0.00 |
| YoY Change | -1800.0% | -100.0% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | -$170.0K | -$602.0K | -$20.00K |
| YoY Change | -1800.0% | 2910.0% | -33.33% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $0.00 | $0.00 | |
| YoY Change | -100.0% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -40.00K | -$41.00K | 60.00K |
| YoY Change | -168.33% | -88.0% | |
| NET CHANGE | |||
| Cash From Operating Activities | -3.570M | -$2.273M | -1.150M |
| Cash From Investing Activities | -170.0K | -$602.0K | -20.00K |
| Cash From Financing Activities | -40.00K | -$41.00K | 60.00K |
| Net Change In Cash | -3.780M | -$2.916M | -1.110M |
| YoY Change | 129.09% | 162.7% | 1010.0% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$3.570M | -$2.273M | -$1.150M |
| Capital Expenditures | -$170.0K | $400.0K | $0.00 |
| Free Cash Flow | -$3.400M | -$2.673M | -$1.150M |
| YoY Change | 103.59% | 132.43% | 96.92% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2016Q3 | us-gaap |
Deferred Revenue
DeferredRevenue
|
0 | USD |
| CY2016Q2 | us-gaap |
Deferred Revenue
DeferredRevenue
|
24000 | USD |
| CY2016Q3 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
0 | USD |
| CY2016Q2 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
22000 | USD |
| CY2016Q2 | us-gaap |
Security Deposit
SecurityDeposit
|
28000 | USD |
| CY2016Q2 | us-gaap |
Minority Interest
MinorityInterest
|
14107000 | USD |
| CY2016Q3 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
20697000 | USD |
| CY2016Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2016Q3 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
173000 | USD |
| CY2016Q3 | us-gaap |
Liabilities
Liabilities
|
27394000 | USD |
| CY2016Q2 | us-gaap |
Liabilities
Liabilities
|
27556000 | USD |
| CY2016Q3 | us-gaap |
Security Deposit
SecurityDeposit
|
26000 | USD |
| CY2016Q3 | us-gaap |
Minority Interest
MinorityInterest
|
13556000 | USD |
| CY2016Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
24044000 | USD |
| CY2016Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
89000 | USD |
| CY2016Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
89000 | USD |
| CY2016Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2016Q2 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
170000 | USD |
| CY2016Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2174000 | USD |
| CY2016Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2291000 | USD |
| CY2016Q3 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
25220000 | USD |
| CY2016Q2 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
25265000 | USD |
| CY2016Q3 | us-gaap |
Unbilled Receivables Current
UnbilledReceivablesCurrent
|
62000 | USD |
| CY2016Q2 | us-gaap |
Unbilled Receivables Current
UnbilledReceivablesCurrent
|
122000 | USD |
| CY2015Q3 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-1110000 | USD |
| CY2016Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
265000 | USD |
| CY2016Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
265000 | USD |
| CY2015Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
329000 | USD |
| CY2016Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
88000 | USD |
| CY2015Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
91000 | USD |
| CY2016Q3 | us-gaap |
Depreciation
Depreciation
|
324000 | USD |
| CY2015Q3 | us-gaap |
Depreciation
Depreciation
|
1000 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-315000 | USD |
| CY2015Q3 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
34000 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-131000 | USD |
| CY2015Q3 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-90000 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
53000 | USD |
| CY2015Q3 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
171000 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
102000 | USD |
| CY2015Q3 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
136000 | USD |
| CY2016Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-2273000 | USD |
| CY2015Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-1147000 | USD |
| CY2016Q3 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
202000 | USD |
| CY2015Q3 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
18000 | USD |
| CY2016Q3 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
400000 | USD |
| CY2015Q3 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | USD |
| CY2016Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-602000 | USD |
| CY2015Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-18000 | USD |
| CY2016Q3 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
0 | USD |
| CY2015Q3 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
63000 | USD |
| CY2016Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-41000 | USD |
| CY2015Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
63000 | USD |
| CY2016Q3 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
0 | USD |
| CY2015Q3 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-8000 | USD |
| CY2016Q3 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-2916000 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
|
-61000 | USD |
| CY2015Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
8384000 | USD |
| CY2015Q3 | ibio |
Unpaid Intangible Assets Included In Accounts Payable
UnpaidIntangibleAssetsIncludedInAccountsPayable
|
0 | USD |
| CY2015Q3 | us-gaap |
Increase Decrease In Finished Goods And Work In Process Inventories
IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
|
0 | USD |
| CY2016Q3 | us-gaap |
Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
|
59850000 | USD |
| CY2016Q3 | us-gaap |
Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
|
70350000 | USD |
| CY2015Q3 | us-gaap |
Capital Leases Income Statement Interest Expense
CapitalLeasesIncomeStatementInterestExpense
|
0 | USD |
| CY2015Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
9494000 | USD |
| CY2016Q3 | ibio |
Unpaid Intangible Assets Included In Accounts Payable
UnpaidIntangibleAssetsIncludedInAccountsPayable
|
184000 | USD |
| CY2016Q3 | ibio |
Unpaid Intangible Assets Included In Accrued Expenses
UnpaidIntangibleAssetsIncludedInAccruedExpenses
|
0 | USD |
| CY2015Q3 | ibio |
Unpaid Intangible Assets Included In Accrued Expenses
UnpaidIntangibleAssetsIncludedInAccruedExpenses
|
-3000 | USD |
| CY2015Q3 | us-gaap |
Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
|
126000 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-24000 | USD |
| CY2015Q3 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
0 | USD |
| CY2016Q3 | us-gaap |
Interest Paid
InterestPaid
|
484000 | USD |
| CY2015Q3 | us-gaap |
Interest Paid
InterestPaid
|
0 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
|
2000 | USD |
| CY2015Q3 | us-gaap |
Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
|
0 | USD |
| CY2016Q3 | us-gaap |
Increase Decrease In Finished Goods And Work In Process Inventories
IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
|
-22000 | USD |
| CY2016Q3 | us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
41000 | USD |
| CY2015Q3 | us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
0 | USD |
| CY2016Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
|
46000 | USD |
| CY2016Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
|
34000 | USD |
| CY2016Q3 | us-gaap |
Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
|
882000 | USD |
| CY2016Q2 | us-gaap |
Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
|
571000 | USD |
| CY2016Q3 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
2023000 | USD |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
2092000 | USD |
| CY2016Q3 | us-gaap |
Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
|
2100000 | USD |
| CY2016Q3 | us-gaap |
Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
|
2100000 | USD |
| CY2016Q3 | us-gaap |
Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
|
2100000 | USD |
| CY2016Q3 | us-gaap |
Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
|
2100000 | USD |
| CY2016Q3 | us-gaap |
Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
|
2100000 | USD |
| CY2016Q3 | us-gaap |
Capital Leases Income Statement Interest Expense
CapitalLeasesIncomeStatementInterestExpense
|
484000 | USD |
| CY2016Q3 | ibio |
Sub Lease Expiration Period
SubLeaseExpirationPeriod
|
P34Y | |
| CY2016Q3 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
2100000 | USD |
| CY2016Q3 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
25000 | USD |
| CY2015Q3 | us-gaap |
Assets
Assets
|
11374000 | USD |
| CY2015Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
10000 | USD |
| CY2015Q3 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
2284000 | USD |
| CY2015Q3 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
8000 | USD |
| CY2016Q3 | ibio |
Long Term Purchase Commitment Expire Date
LongTermPurchaseCommitmentExpireDate
|
2015-12-31 | |
| CY2016Q3 | us-gaap |
Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
|
200000 | USD |
| CY2016Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
265000 | USD |
| CY2015Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
329000 | USD |
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
433000 | USD |
| CY2016Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
405000 | USD |
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
2700000 | shares |
| CY2016Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-3061000 | USD |
| CY2015Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-1805000 | USD |
| CY2016Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
4043000 | USD |
| CY2015Q2 | ibio |
Registration Common Stock
RegistrationCommonStock
|
15000000 | USD |
| CY2016Q3 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2016Q3 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2016Q3 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2016-09-30 | |
| CY2016Q3 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | |
| CY2016Q3 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2016Q3 | dei |
Entity Registrant Name
EntityRegistrantName
|
iBio, Inc. | |
| CY2016Q3 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001420720 | |
| CY2016Q3 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--06-30 | |
| CY2016Q3 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2016Q3 | dei |
Trading Symbol
TradingSymbol
|
IBIO | |
| CY2016Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
89109410 | shares |
| CY2015Q3 | us-gaap |
Interest Expense Related Party
InterestExpenseRelatedParty
|
0 | USD |
| CY2016Q3 | us-gaap |
Interest Expense Related Party
InterestExpenseRelatedParty
|
483000 | USD |
| CY2016Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2016Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2016Q3 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">1.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Nature of Business</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on the commercialization of its proprietary plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The advantages of iBio’s technology include reduced production time, capital and operating costs for biopharmaceuticals and the ability to manufacture therapeutic proteins that are difficult or commercially infeasible to produce with conventional methods.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company’s wholly-owned and majority-owned subsidiaries are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBioDefense Biologics LLC (“iBioDefense”) – iBioDefense, a wholly-owned subsidiary, is a Delaware limited liability company formed in July 2013 to explore development and commercialization of defense-specific applications of the Company’s proprietary technology. iBioDefense did not commence any business activities and was dissolved on June 10, 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio Peptide Therapeutics LLC (“iBio Peptide”) – iBio Peptide, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2013. iBio Peptide did not commence any business activities and was dissolved on June 9, 2016.</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBIO DO BRASIL BIOFARMACÊUTICA LTDA. (“iBio Brazil”) – iBio Brazil is a subsidiary organized in Brazil in which the Company has a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 99</font>% interest. iBio Brazil was formed to manage and expand the Company’s business activities in Brazil. The activities of iBio Brazil are intended to include coordination and expansion of the Company’s existing relationship with Fundacao Oswaldo Cruz/Fiocruz (“Fiocruz”) beyond the current Yellow Fever Vaccine program (see Note 7) and development of additional products with private sector participants for the Brazilian market. iBio Brazil commenced operations during the first quarter of the fiscal year ended June 30, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio Manufacturing LLC (“iBio Manufacturing”) – iBio Manufacturing, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2015. iBio Manufacturing has not commenced any activities to date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio CMO LLC (“iBio CMO”) – iBio CMO is a Delaware limited liability company formed on December 16, 2015 to develop and manufacture plant-made pharmaceuticals. As of December 31, 2015, the Company owned <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of iBio CMO. On January 13, 2016, the Company entered into a contract manufacturing joint venture with an affiliate of Eastern Capital Limited (“Eastern”), a stockholder of the Company (the “Eastern Affiliate”). The Eastern Affiliate contributed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font> million in cash for a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font>% interest in iBio CMO. The Company retained a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% interest in iBio CMO and contributed a royalty bearing license which grants iBio CMO a non-exclusive license to use the Company’s proprietary technologies for research purposes and an exclusive U.S. license for manufacturing purposes. The Company retained the exclusive right to grant product licenses to those who wish to sell or distribute products made using the Company’s technologies.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio CMO’s operations take place in Bryan, Texas in a facility controlled by another affiliate of Eastern (the “Second Eastern Affiliate”) as sublandlord. The facility is a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 139,000</font> square foot Class A life sciences building on the campus of Texas A&M University, designed and equipped for plant-made manufacture of biopharmaceuticals. The Second Affiliate granted iBio CMO a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34</font>-year sublease for the facility as well as certain equipment (see Note 8). Commercial operations commenced in January 2016. iBio CMO expects to operate on the basis of three parallel lines of business: (1) Development and manufacturing of third party products; (2) Development and production of iBio’s proprietary product(s) for treatment of fibrotic diseases; and (3) Commercial technology transfer services.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2016Q3 | us-gaap |
Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
|
239000 | USD |
| CY2016Q2 | us-gaap |
Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
|
200000 | USD |
| CY2016Q3 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
772000 | USD |
| CY2016Q2 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
623000 | USD |
| CY2016Q3 | us-gaap |
Preferred Stock No Par Value
PreferredStockNoParValue
|
0 | |
| CY2016Q2 | us-gaap |
Preferred Stock No Par Value
PreferredStockNoParValue
|
0 | |
| CY2016Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
175000000 | shares |
| CY2016Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | shares |
| CY2016Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | shares |
| CY2016Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2016Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2016Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2016Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2016Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
89109410 | shares |
| CY2016Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
89109410 | shares |
| CY2016Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
89109410 | shares |
| CY2016Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
89109410 | shares |
| CY2016Q2 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
6500000 | shares |
| CY2016Q3 | us-gaap |
Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
|
239000 | USD |
| CY2015Q3 | us-gaap |
Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
|
227000 | USD |
| CY2016Q3 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
36000 | USD |
| CY2015Q3 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
0 | USD |
| CY2016Q3 | us-gaap |
Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
|
175000 | USD |
| CY2015Q3 | us-gaap |
Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
|
0 | USD |
| CY2016Q3 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2016Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
26508000 | USD |
| CY2016Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
26179000 | USD |
| CY2016Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
928000 | USD |
| CY2016Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
605000 | USD |
| CY2016Q3 | ibio |
Revenue From Intersegment
RevenueFromIntersegment
|
0 | USD |
| CY2016Q3 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
5384000 | USD |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
5365000 | USD |
| CY2016Q3 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
3361000 | USD |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
3273000 | USD |
| CY2015Q3 | ibio |
Revenue From Intersegment
RevenueFromIntersegment
|
0 | USD |
| CY2016Q3 | ibio |
Capital Lease Obligation Description
CapitalLeaseObligationDescription
|
The base rent under the sublease will be increased by any increase in the base rent under the ground lease as a result of such adjustments. In addition to the base rent, iBio CMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CMO’s applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to $16,000 and $0 in Fiscal 2017 and Fiscal 2016, respectively. | |
| CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
12273334 | shares |
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | shares |
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
12273334 | shares |
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
12233897 | shares |
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
9361697 | shares |
| CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.31 | |
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.31 | |
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
1.31 | |
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
1.31 | |
| CY2016Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P5Y6M | |
| CY2016Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P6Y1M6D | |
| CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y4M24D | |
| CY2016Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y1M6D | |
| CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
993000 | USD |
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
433000 | USD |
| CY2015Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
175000000 | shares |
| CY2016Q3 | ibio |
Unpaid Fixed Assets Included In Accounts Payable
UnpaidFixedAssetsIncludedInAccountsPayable
|
71000 | USD |
| CY2015Q3 | ibio |
Unpaid Fixed Assets Included In Accounts Payable
UnpaidFixedAssetsIncludedInAccountsPayable
|
0 | USD |
